Hawaii 2026 Regular Session

Hawaii Senate Bill SB3206

Introduced
1/28/26  

Caption

RELATING TO CANNABINOIDS.

Summary

SB3206 would amend Hawaii’s hemp laws to create a specific exception allowing permitted hemp processors to sell certain manufactured hemp products that contain hemp-derived cannabinoids, including gummies, beverages, tinctures, and hemp flowers, subject to THC limits and packaging restrictions. For gummies, the bill sets a serving size of one gummy, caps THC at five milligrams per gummy, and limits each package to ten gummies. Beverages would be limited to five milligrams of THC per container, and hemp flowers would be limited to five milligrams of THC per serving. The bill also bars sales of these products to anyone under 21. The measure would also revise existing statutory definitions in Chapter 328G. It expands the definition of “manufactured hemp product” to include floral materials and changes the definition of “tincture” to allow up to five milligrams of THC per serving, replacing the current lower limit. In addition, it modifies the general prohibition on adding cannabinoids to food by carving out an exception for the products authorized in the new section, while preserving Department of Health rulemaking authority and an exception for FDA-recognized GRAS hemp ingredients.

Impact

If enacted, SB3206 would directly change Hawaii Revised Statutes chapter 328G by expanding the range of hemp-derived cannabinoid products that licensed hemp processors may legally sell and by loosening THC limits for tinctures. It would also create a new statutory framework for gummies, beverages, tinctures, and hemp flowers, impose age restrictions, and require compliance with all other applicable hemp and food laws. The bill would affect hemp processors, retailers, the Department of Health, and consumers, particularly by opening a regulated market for products that are currently restricted or more tightly limited under existing law.

Sentiment

The available context suggests the bill was introduced as a regulatory expansion for the hemp industry, with a focus on clarifying what products may be sold and under what THC thresholds. The report title and description frame the measure as a controlled allowance for hemp processors rather than a broad legalization of intoxicating cannabis products. However, the committee on CPN deferred the measure, indicating that it did not advance at that stage and that there may have been unresolved concerns or insufficient support.

Contention

The main points of contention appear to center on the policy choice to permit hemp-derived cannabinoid products with measurable THC content in consumer goods, especially gummies and beverages, and to raise the THC limit for tinctures. Potential concerns include youth access, product safety, labeling, and the boundary between hemp products and regulated cannabis. The bill’s exception to the food prohibition also suggests tension with existing restrictions on cannabinoids in food, while the Department of Health’s role in rulemaking indicates that implementation details may have been a subject of debate. The lack of recorded votes or transcripts limits the ability to identify specific opponents or supporters.

Companion Bills

No companion bills found.

Previously Filed As

HI SB1655

Relating To Manufactured Hemp Products.

HI SB1633

Relating To Hemp.

HI SB620

Relating To Hemp.

HI HB1482

Related To Controlled Substances.

HI SB1430

Relating To Registration To Sell Manufactured Hemp Products.

HI HB1111

Relating To Registration To Sell Manufactured Hemp Products.

HI SB1064

Relating To Medical Cannabis.

HI SB1428

Relating To Manufactured Hemp Products.

HI SB1427

Relating To Manufactured Hemp Products.

HI HB1109

Relating To Manufactured Hemp Products.

Similar Bills

No similar bills found.